You can seek FDA approval to launch a generic drug before the expiration of ACTOPLUS MET XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTOPLUS MET XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTOPLUS MET XR:-

You can seek FDA approval to launch a generic drug before the expiration of ACTOS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTOS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTOS:-

You can seek FDA approval to launch a generic drug before the expiration of ADDERALL XR 10's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADDERALL XR 10's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADDERALL XR 10:-

You can seek FDA approval to launch a generic drug before the expiration of ADDERALL XR 15's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADDERALL XR 15's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADDERALL XR 15:-

You can seek FDA approval to launch a generic drug before the expiration of ADDERALL XR 20's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADDERALL XR 20's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADDERALL XR 20:-

You can seek FDA approval to launch a generic drug before the expiration of ADDERALL XR 25's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADDERALL XR 25's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADDERALL XR 25:-

You can seek FDA approval to launch a generic drug before the expiration of ADDERALL XR 30's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADDERALL XR 30's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADDERALL XR 30:-

You can seek FDA approval to launch a generic drug before the expiration of ADDERALL XR 5's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADDERALL XR 5's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADDERALL XR 5:-

You can seek FDA approval to launch a generic drug before the expiration of CARBATROL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CARBATROL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CARBATROL:-

You can seek FDA approval to launch a generic drug before the expiration of COLCRYS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COLCRYS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COLCRYS:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of DEXILANT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DEXILANT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DEXILANT:-

You can seek FDA approval to launch a generic drug before the expiration of DUETACT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DUETACT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DUETACT:-

You can seek FDA approval to launch a generic drug before the expiration of FIRAZYR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FIRAZYR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FIRAZYR:-

You can seek FDA approval to launch a generic drug before the expiration of FOSRENOL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FOSRENOL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FOSRENOL:-

You can seek FDA approval to launch a generic drug before the expiration of ICLUSIG's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ICLUSIG's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ICLUSIG:-

You can seek FDA approval to launch a generic drug before the expiration of INTUNIV's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the INTUNIV's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on INTUNIV:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of KAZANO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KAZANO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KAZANO:-

You can seek FDA approval to launch a generic drug before the expiration of LIALDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LIALDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LIALDA:-

You can seek FDA approval to launch a generic drug before the expiration of MYDAYIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MYDAYIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MYDAYIS:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of NESINA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NESINA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NESINA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of NINLARO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NINLARO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NINLARO:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of PREVACID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PREVACID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PREVACID:-

You can seek FDA approval to launch a generic drug before the expiration of ROZEREM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ROZEREM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ROZEREM:-